The Frost & Sullivan Award for Entrepreneurial Company is given each year to the small company that demonstrated superior entrepreneurial ability in its industry during the research period. This Award signifies the company's identification of a unique and revolutionary product solution with significant market potential. Additionally, the Award certifies that the company's marketing strategy is sound and poised for success.
Entrepreneurial ability is assessed using mostly primary research with top manufacturers and end-users in the industry. Frost & Sullivan analyst teams perform extensive interviews with the company in question to evaluate its products, business, and marketing plan. In addition, primary research with leading manufacturers is performed to benchmark the Award recipient's strategy for growth against established players' strategies. Also considered are elements such as strategic alliances, expected time to market, and the senior management team. Primary research with end-users is also conducted to evaluate and compare the value of the Award recipient’s product solution.
A recipient that is chosen for the Frost & Sullivan Award for Entrepreneurial Company must match the following criteria:
The 2006 Frost &Sullivan Entrepreneurial Company Award is presented to Debiotech for its superior entrepreneurial capabilities and competitive technologies. The company is recognised for its unique product – Insulin nanopump, which is poised to revolutionise the European insulin pump market.
Debiotech was founded 16 years ago in 1990. With 50 employees in the organisation, it focuses on the development of innovative drug delivery systems. It is a dynamic organisation that incorporates cutting edge technologies to introduce innovative medical devices. Debiotech integrates the best research and development (R&D) skills with successful collaboration of major organisations to cater to the healthcare industry.
Debiotech’s growth can be directly attributed to continuous investments in its product innovation and process technology innovations. In order to cater to the ever increasing demands from the healthcare industry, Debiotech focuses on cost effective innovations.
The mission of this organization is to reduce the increasing gap between discovery and commercialization through product innovation. The company researches on technologies like micro and nanotechnology, microelectronics and micromechanics so as to introduce innovative medical devices for use in both therapeutic and diagnostic areas.
Debiotech enjoys the benefits of an efficient management team that prudently strings the various functional departments in the R&D sector. It offers an efficient interface so as to shrink the timeline between breakthrough technology identification and product commercialization.
Chart 13.2 depicts the mission of Debiotech as an entrepreneurial company.
Debiotech is poised to enter the diabetes market with its innovative Insulin Nano pump. This product is estimated to garner $200.0 million within a couple of years of launch. The insulin nanopump offers to address some major obstacles faced in the current insulin pumps. This new technology makes insulin delivery an easy and virtually painless process. It is based on the MEMS NanoPump Technology.
The major barrier to effective diabetes management is the size of the drug delivery pumps. This is addressed by the Insulin NanoPump, which is five times smaller than the conventional pump. Added features of increased insulin reservoir size and precise reproducibility of insulin dose resulting in accurate dosing regimen are bound to provide diabetic patients an option for better diabetes management. In addition, the safety measures in the insulin pump have been geared up to provide the best insulin delivery device for the patients. As it is likely to be more affordable to patients, this Insulin NanoPump is expected to be a surefire hit among the insulin taking diabetic population.
Debiotech focuses on various advanced drug delivery systems that are designed to meet the unmet needs in different therapeutic areas. The organization is mustering its resources to bring out advanced, cost effective and innovative electronic infusion systems, diagnostics, nano and microsystems. The quality and safety features of the devices have been given great importance. Debiotech has been offered the ISO 9001/EN46001 and ISO 13485 certification for quality standards. The focus on quality of the products enables this organization to deliver the best to the healthcare community.
Valuable partnership deals are forged in both the industrial sector as well as the R&D sector. The objective of incorporating external excellence by collaborating with external organizations to aid in its committed role of delivering innovations to the healthcare community endorses Debiotech as an Entrepreneurial company. Debiotech is into various partnering agreements like centre of Microtechnology (CMI) and Ecole Polytechnique Fédérale de Lausanne (EPFL) for the development of innovative technologies. In addition, Debiotech has agreements with major medical device and pharmaceutical companies for marketing its products. With strong marketing back up provided by strategic alliances, Debiotech is poised for success.
Debiotech believes in continuous improvement. It adheres to the principle that there is no challenge greater than maintaining consistent delivery, laying emphasis on quality, speed and innovation. The company’s focus on customer satisfaction, product line diversification and constant innovation has reflected on its innovative products. Based on these cumulative factors the 2006 Frost & Sullivan Entrepreneurial Company Award is presented to Debiotech.
Avenue de Sevelin, 28
CH-1004 Lausanne, Switzerland
Learn more :Insulin Pump>>
Debiotech S.A., Av. de Sévelin 28, 1004 Lausanne, Switzerland.
© Copyright 1995-2006 Debiotech S.A. All rights reserved.